sardomozide (SAM486) / Novartis - LARVOL DELTA

The Polyamine Inhibitor SAM486 Increases Adagrasib Efficacy in Non-Small Cell Lung Cancer Cells Bearing G12C Mutation (LALCA 2024) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Synergistic enhancement of KRASG12C inhibitor adagrasib by AMD1 inhibitor SAM486 in non-small cell lung cancer: in vitro and in vivo studies (EORTC-NCI-AACR 2024) - "These findings suggest that the combination of the KRASG12C inhibitor adagrasib and the AMD1 inhibitor SAM486 could provide a novel and synergistic therapeutic strategy against tumors with KRASG12C mutations."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • PCNA

Polyamine Inhibitor SAM486A Augments Cytarabine Cytotoxicity in Methylthioadenosine Phosphorylase-deficient Leukemia Cells. (PubMed, Anticancer Res) - "Methionine metabolism and polyamine synthesis can be attractive therapeutic targets in leukemia."

Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • MTAP